Aetna Better Health® of New Jersey

Protocol for molnupiravir capsules

January 2022

Indication (Emergency Use Authorization only):

Molnupiravir is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID19) in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate.

Criteria for approval:

1. Patient is 18 year and older
2. **Molnupiravir** will be approved for FDA-approved indications ONLY
3. **Approval will be for no more than 8 tablets per day and no more than 40 tablets per 90 days**
4. Higher doses or quantities will be approved with evidence of medical necessity

Dose:

800 mg PO q12hr for 5 days

Initiate as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset

References:

1. Fact sheet for Healthcare Providers: Emergency Use Authorization for molnupiravar. Merck & Co. Inc. Whitehouse Station, NJ 08889. December 2021.
2. Clinical Pharmacology® Gold Standard Series [Internet database]. Tampa FL. Elsevier 2019. Updated periodically
3. Reduced Risk of Reinfection with SARS-Cov-2 After COVID-19 Vaccination – Kentucky, May-June 2021. Us Department of Health and Human Services/centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. Vol. 70(32) August 13, 2021
4. Ending Isolation and Precautions for People with COVID-19: Interim Guidance. Centers for Disease Control and Prevention (CDC) Last updated: Dec 28, 2021. https://www.cdc.gov/coronavirus/2019-neov/hcp/duration-isolation.html.